Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Candel Therapeutics, Inc. (CADL)
Company Research
Source: Yahoo! Finance
Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024 On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024 NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “It was a catalyst-rich first quarter for Candel, marked by significant advances across both our clinical and preclinical programs,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “Notably, as our clinical data mature with long-term follow up, we are beginning to observe highly differentiated results in
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments [Yahoo! Finance]Yahoo! Finance
- Oncolytic Virus Cancer Therapy Pipeline Analysis, 2024 - Showing Promise with Over 120 Companies and 125 Drugs in Development [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics to Join Russell 3000® Index [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics to Join Russell 3000® IndexGlobeNewswire
- Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
CADL
Earnings
- 11/9/23 - Miss
CADL
Sec Filings
- 5/30/24 - Form ARS
- 5/30/24 - Form DEF
- 5/30/24 - Form 8-K
- CADL's page on the SEC website